Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H34O4 |
Molecular Weight | 386.5244 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C[C@H](C)C4=CC(=O)CC[C@]34C
InChI
InChIKey=PSGAAPLEWMOORI-PEINSRQWSA-N
InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
Molecular Formula | C24H34O4 |
Molecular Weight | 386.5244 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:00:43 UTC 2023
by
admin
on
Fri Dec 15 15:00:43 UTC 2023
|
Record UNII |
C2QI4IOI2G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
141901
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
||
|
IARC | Medroxyprogesterone acetate | ||
|
WHO-ESSENTIAL MEDICINES LIST |
18.3.2
Created by
admin on Fri Dec 15 15:00:44 UTC 2023 , Edited by admin on Fri Dec 15 15:00:44 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.7
Created by
admin on Fri Dec 15 15:00:44 UTC 2023 , Edited by admin on Fri Dec 15 15:00:44 UTC 2023
|
||
|
NCI_THESAURUS |
C776
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.3.2 (EST/MED)
Created by
admin on Fri Dec 15 15:00:44 UTC 2023 , Edited by admin on Fri Dec 15 15:00:44 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
21171
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
MEDROXYPROGESTERONE ACETATE
Created by
admin on Fri Dec 15 15:00:44 UTC 2023 , Edited by admin on Fri Dec 15 15:00:44 UTC 2023
|
PRIMARY | Description: A white or almost white, crystalline powder. Solubility: Practically insoluble in water; soluble in acetone R and dioxan R; slightly soluble in ethanol (~750 g/L) TS, methanol Rand ether R. Category: Progestogen. Storage: Medroxyprogesterone acetate should be kept in a tight container, protected from light. Definition: Medroxyprogesterone acetate contains not less than 97.0% and not more than the equivalent of 103.0% of C24H34O4,calculated with reference to the dried substance. | ||
|
1000112
Created by
admin on Fri Dec 15 15:00:44 UTC 2023 , Edited by admin on Fri Dec 15 15:00:44 UTC 2023
|
PRIMARY | RxNorm | ||
|
DMPA
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
D017258
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
26386
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
SUB03114MIG
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
71-58-9
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
SUB127224
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
ALTERNATIVE | |||
|
C2QI4IOI2G
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
C2QI4IOI2G
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
DB00603
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
6716
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
C1155
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
100000091612
Created by
admin on Fri Dec 15 15:00:44 UTC 2023 , Edited by admin on Fri Dec 15 15:00:44 UTC 2023
|
PRIMARY | |||
|
m7134
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | Merck Index | ||
|
MEDROXYPROGESTERONE ACETATE
Created by
admin on Fri Dec 15 15:00:44 UTC 2023 , Edited by admin on Fri Dec 15 15:00:44 UTC 2023
|
PRIMARY | |||
|
200-757-9
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
1378001
Created by
admin on Fri Dec 15 15:00:44 UTC 2023 , Edited by admin on Fri Dec 15 15:00:44 UTC 2023
|
PRIMARY | |||
|
CHEMBL717
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
DTXSID0025527
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY | |||
|
6279
Created by
admin on Fri Dec 15 15:00:44 UTC 2023 , Edited by admin on Fri Dec 15 15:00:44 UTC 2023
|
PRIMARY | |||
|
Medroxyprogesterone Acetate
Created by
admin on Fri Dec 15 15:00:43 UTC 2023 , Edited by admin on Fri Dec 15 15:00:43 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (UV)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity E.
In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity C, E or I is not greater than 2 times the area of the principal peak obtained with solution (3) (0.2%).
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
The following peaks are eluted at the following relative retention with reference to the peak of medroxyprogesterone acetate (retention time about 27 minutes): impurity C about 0.8. The test is not valid unless in the chromatogram obtained with solution (4) the resolution factor between the peaks due to impurity G and due to medroxyprogesterone acetate is at least 3.3. In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity C, E or I is not greater than 2 times the area of the principal peak obtained with solution (3) (0.2%).
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity I.
The following peaks are eluted at the following relative retention with reference to the peak of medroxyprogesterone acetate (retention time about 27 minutes): impurity I about 0.5. In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity C, E or I is not greater than 2 times the area of the principal peak obtained with solution (3) (0.2%).
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 2.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity F.
Amount not specified.
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity H.
The following peaks are eluted at the following relative retention with reference to the peak of medroxyprogesterone acetate (retention time about 27 minutes): impurity H about 0.65.
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.8
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity B. In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity B is not greater than 0.7 times the area of the principal peak obtained with solution (2) (0.7%).
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity G.
In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity G, when multiplied by a correction factor of 2.6, is not greater than 2 times of the area of the principal peak obtained with solution (3) (0.2%).
|
||
|
PARENT -> IMPURITY |
For the calculation of contents, multiply the peak areas by 0.2
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity D.
In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity D is not greater than the area of the principal peak obtained with solution (2) (1.0%).
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity A.
In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity A, when multiplied by a correction factor of 1.5, is not greater than 3 times of the area of the principal peak obtained with solution (3) (0.3%).
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |